PASW in three months: buy, wait or sell?
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
- Buy / Wait / Sell rating
- 3-month target price
- Bear · Base · Bull
- vs. the market
What happened with PASW today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ping An Biomedical operates an apparel supply-chain business through its Chinese subsidiary New Brand. Textile manufacturers, clothing brands and retailers in China pay it to supply products made to their requirements. It helps develop designs, sources materials, arranges production with independent manufacturers, checks quality and organizes delivery rather than making most products itself.
Most revenue comes from yarn products; finished garments contribute a smaller share. Knitted panels—yarn processed into pieces to manufacturers’ specifications—are a significant part of sales. The company generally sets selling prices by adding a markup to the costs of materials, outsourced manufacturing and transport, so earnings depend on controlling those costs and passing increases on to customers.
A handful of customers provide most revenue, with one accounting for a particularly large share. They buy order by order and have no long-term purchase commitments. The business also relies on outside suppliers without long-term contracts to meet price, quality and delivery requirements. At the holding-company level, access to New Brand’s earnings is limited by Chinese rules on distributable profits, required reserves and overseas remittances.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Despite its biomedical name, Ping An Biomedical depends on Chinese demand for cashmere yarn, volatile yarn costs and orders from a handful of customers with no long-term purchase commitments.
Neo-Concept shares Ping An Biomedical’s exposure to cashmere and wool costs and knitwear demand: it arranges outsourced apparel production for North American and European customers and sells cashmere knitwear in the UK and UAE, while Ping An sells yarn and knitted panels to customers in China. Watch sales of Neo-Concept’s les 100 ciels cashmere knitwear for a read on demand, but not as a direct gauge of Ping An’s Chinese orders.
No upcoming items to show.
Earnings, filings and other dated events show up here once their dates are set.